Elsevier

Advances in Dermatology

Volume 24, November 2008, Pages 71-87
Advances in Dermatology

Toll-Like Receptors in Skin

https://doi.org/10.1016/j.yadr.2008.09.004Get rights and content

Section snippets

Editorial Comment

Dr. Miller and his colleagues at the University of California - Los Angeles have been national leaders in elucidating the roles of a family of proteins called Toll-like receptors (TLRs) in processes as diverse as Staphylococcus aureus skin infections, acne vulgaris, and leprosy infection. TLRs are a highly conserved family of pattern recognition receptors that have emerged as critical sensors of bacterial, fungal, and viral pathogens by recognizing conserved components of these microorganisms,

Innate and adaptive immunity

Innate immunity was once considered to be an early nonspecific proinflammatory response whose primary function was to recruit and activate phagocytes such as neutrophils and monocytes/macrophages to phagocytize microorganisms [9], [10]. It is now known that the innate immune response has considerable specificity that is directed against conserved molecular patterns of components of microorganisms, which are called pathogen-associated molecular patterns (PAMPs) [9], [10]. The receptors on immune

Toll-like receptors

TLRs are transmembrane glycoproteins that contain an ectodomain of leucine-rich motifs, which is involved in recognition of components of microbes [6], [7], [8]. TLRs also contain a transmembrane domain and a cytoplasmic tail domain that is homologous to the interleukin-1 receptor and is responsible for initiating various intracellular signaling cascades (Fig. 1) [6], [7], [8]. These signaling cascades include activation of nuclear factor-κB (NF-κB), which is a key transcription factor that

Toll-like receptor signaling and immune responses

Activation of TLRs by their ligands results in initiation of several signaling cascades, which eventually result in expression of cytokines (eg, tumor necrosis factor [TNF]α, interleukin [IL]-1β, IL-6, IL-12), chemokines (IL-8, growth-regulated oncogene [GRO]-α, monocyte chemoattractant protein [MCP]-1, -2, -3, -4, macrophage inflammatory protein [MIP]1α/β, and Regulated upon Activation, Normal T-cell Expressed, and Secreted [RANTES]), antimicrobial peptides, (beta-defensins and cathelicidin),

Toll-like receptors can induce a vitamin D–dependent antimicrobial pathway

Recently, Liu and colleagues [15], [16] demonstrated that activation of TLR2/1 on human monocytes/macrophages up-regulated a vitamin D-1-hydroxylase (CYP27B1) and the vitamin D receptor (VDR) (Fig. 4). This activity of TLR2/1 resulted in the conversion of the inactive form of vitamin D (25D3) to its active form (1,25D3), which subsequently activated the VDR and led to the production of the antimicrobial peptide cathelicidin [15], [16]. Since cathelicidin has microbicidal activity against a

Toll-like receptor expression and function of skin-specific cells

There are many different cell types in human skin that express TLRs [1], [2], [3]. In the epidermis, keratinocytes have been shown to express functional TLRs. In addition, there are resident and trafficking immune system cells in the skin that express TLRs, including Langerhans cells (LCs), monocytes/macrophages, dendritic cells (DCs), T and B lymphocytes, and mast cells [1], [2], [3]. Last, endothelial cells of the microvasculature and stromal cells such as fibroblasts and adipocytes also

Atopic dermatitis

Atopic dermatitis or eczema is an inflammatory skin disease that is associated with a hereditary predisposition to atopic conditions, which include allergic rhinitis, allergic keratoconjuntivitis, asthma, and eczema [5]. Clinically, atopic dermatitis is characterized by the presence of inflammatory skin lesions that are extremely pruritic [5]. Like other allergic diseases, the pathophysiology of atopic dermatitis involves a Th-2 type immune response in the skin. The role of TLRs in the

Staphylococcus aureus

S aureus is a gram-positive bacterium that is the most common cause of bacterial skin infections in humans such as impetigo, folliculitis/furunculosis, and cellulitis. TLR2 has been shown to recognize various components of S aureus, including peptidoglycan and lipopeptides [62], [63], [64]. In addition, the TLR2/6 heterodimer along with CD36 has been shown to recognize S aureus lipoteichoic acid [65]. A recent study demonstrated that TLR2 on primary human keratinocytes contributed to

Summary

TLRs have emerged as a major class of PRRs that are involved in detecting invading pathogens in the skin and initiating cutaneous immune responses. TLRs are expressed on many different cell types in the skin, including keratinocytes and Langerhans cells in the epidermis. Each TLR can recognize a different microbial component and there are differences among the TLR signaling pathways, which lead to distinct immune responses against a given pathogen. Certain TLRs have been implicated in the

First page preview

First page preview
Click to open first page preview

References (89)

  • R.P. Burns et al.

    The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans cells

    Clin Immunol

    (2000)
  • M.D. Howell et al.

    Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus

    Immunity

    (2006)
  • P. Ahmad-Nejad et al.

    The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype

    J Allergy Clin Immunol

    (2004)
  • S. Weidinger et al.

    Lack of association between toll-like receptor 2 and toll-like receptor 4 polymorphisms and atopic eczema

    J Allergy Clin Immunol

    (2006)
  • H. Hasannejad et al.

    Selective impairment of toll-like receptor 2-mediated proinflammatory cytokine production by monocytes from patients with atopic dermatitis

    J Allergy Clin Immunol

    (2007)
  • T. Henseler et al.

    Disease concomitance in psoriasis

    J Am Acad Dermatol

    (1995)
  • J. Harder et al.

    Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic

    J Biol Chem

    (2001)
  • K.A. Fitzgerald et al.

    The role of the interleukin-1/toll-like receptor superfamily in inflammation and host defence

    Microbes Infect

    (2000)
  • O. Takeuchi et al.

    Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

    Immunity

    (1999)
  • N.W. Schroder et al.

    Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved

    J Biol Chem

    (2003)
  • L.S. Miller et al.

    MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus

    Immunity

    (2006)
  • S.L. Walker et al.

    Leprosy

    Clin Dermatol

    (2007)
  • T.J. Kang et al.

    A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy

    Cytokine

    (2002)
  • T.J. Kang et al.

    Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients

    FEMS Immunol Med Microbiol

    (2001)
  • G.M. Barton

    Viral recognition by Toll-like receptors

    Semin Immunol

    (2007)
  • L.S. Miller et al.

    Toll-like receptors in the skin

    Semin Immunopathol

    (2007)
  • T.S. Kupper et al.

    Immune surveillance in the skin: mechanisms and clinical consequences

    Nat Rev Immunol

    (2004)
  • A. Iwasaki et al.

    Toll-like receptor control of the adaptive immune responses

    Nat Immunol

    (2004)
  • G. Trinchieri et al.

    Cooperation of Toll-like receptor signals in innate immune defence

    Nat Rev Immunol

    (2007)
  • R. Medzhitov

    Toll-like receptors and innate immunity

    Nat Rev Immunol

    (2001)
  • R. Medzhitov et al.

    Innate immunity

    N Engl J Med

    (2000)
  • M. Schiller et al.

    Immune response modifiers—mode of action

    Exp Dermatol

    (2006)
  • A.K. Gupta et al.

    Viral and nonviral uses of imiquimod: a review

    J Cutan Med Surg

    (2004)
  • R.L. Modlin et al.

    From plankton to pathogen recognition

    Nat Med

    (2004)
  • L.A. O'Neill et al.

    The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

    Nat Rev Immunol

    (2007)
  • P.T. Liu et al.

    Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin

    J Immunol

    (2007)
  • P.T. Liu et al.

    Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response

    Science

    (2006)
  • J. Schauber et al.

    Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism

    J Clin Invest

    (2007)
  • C. Robert et al.

    Inflammatory skin diseases, T cells, and immune surveillance

    N Engl J Med

    (1999)
  • B.S. Baker et al.

    Normal keratinocytes express toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis

    Br J Dermatol

    (2003)
  • E. Begon et al.

    Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin

    Eur J Dermatol

    (2007)
  • J.L. Curry et al.

    Innate immune-related receptors in normal and psoriatic skin

    Arch Pathol Lab Med

    (2003)
  • K. Kawai

    Expression of functional toll-like receptors on cultured human epidermal keratinocytes

    J Invest Dermatol

    (2003)
  • M.C. Lebre et al.

    Double-stranded RNA-exposed human keratinocytes promote Th1 responses by inducing a Type-1 polarized phenotype in dendritic cells: role of keratinocyte-derived tumor necrosis factor alpha, type I interferons, and interleukin-18

    J Invest Dermatol

    (2003)
  • Cited by (212)

    • Acne Treatment Strategies 2023

      2023, Advances in Cosmetic Surgery
    View all citing articles on Scopus
    View full text